Acurx Pharmaceuticals is a clinical‑stage biopharma developing a new class of antibiotics that inhibit DNA polymerase IIIC, a novel bacterial target. Their oral and injectable candidates aim to treat high‑priority Gram‑positive infections such as C. difficile, VRE, MRSA, and resistant Streptococcus, addressing the growing need for effective therapies against resistant pathogens.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibiotic development has stalled, and existing drug classes are increasingly ineffective against priority bacterial pathogens such as Clostridioides difficile, vancomycin‑resistant Enterococcus, methicillin‑resistant Staphylococcus aureus, and resistant Streptococcus species. The lack of new mechanisms of action contributes to rising morbidity, mortality, and healthcare costs.
Solution
Acurx Pharmaceuticals is developing a new class of antibiotics that inhibit DNA polymerase IIIC (Pol IIIC), a molecular target not previously exploited in clinical therapy. By blocking this essential enzyme, the candidates aim to provide potent activity against Gram‑positive bacteria, including strains resistant to existing drugs. The pipeline includes both oral and parenteral formulations designed for treatment of infections caused by C. difficile, VRE, MRSA, and resistant Streptococcus. Early‑stage studies have demonstrated target engagement and antibacterial efficacy, and the program is advancing through clinical development to address urgent public‑health threats identified by the WHO, CDC, and FDA.
Target Audience
Primary customers are healthcare providers and hospital systems treating serious Gram‑positive infections, as well as public‑health agencies and pharmaceutical partners seeking novel antibiotics for resistant bacterial threats.
Features
- Novel mechanism of action targeting DNA polymerase IIIC, a previously untapped bacterial enzyme
- Oral and injectable formulations to support flexible treatment settings
- Broad-spectrum activity against high‑priority Gram‑positive pathogens, including C. difficile, VRE, MRSA, and resistant Streptococcus
- Clinical‑stage development with demonstrated target inhibition and antibacterial activity in preclinical models
- Alignment with regulatory incentives for qualified infectious disease products (QIDP) under the GAIN Act